The outcome of Mycobacterium tuberculosis (Mtb) infection and the immunological 23 response to the Bacille Calmette Guerin (BCG) vaccine are highly variable in humans. Deciphering the 24 relative importance of host genetics, environment, and vaccine preparation on BCG efficacy has 25 determinant of vaccine efficacy and provides a model system to develop interventions that will be 51 useful in genetically diverse populations. 52 53
proven difficult in natural populations. We developed a model system that captures the breadth of 26 immunological responses observed in outbred individuals, which can be used to understand the 27 contribution of host genetics to vaccine efficacy. This system employs a panel of highly-diverse 28 inbred mouse strains, consisting of the founders and recombinant progeny of the "Collaborative 29 immunological response to infection, and were not durably protected by BCG vaccination. However, 34 when analyzed at the genotype level, we found that these phenotypic differences were heritable. Mtb 35 susceptibility varied between lines, from extreme sensitivity to progressive Mtb clearance. Similarly, 36 only a minority of the genotypes was protected by vaccination. BCG efficacy was genetically 37 separable from susceptibility, and the lack of efficacy in the aggregate analysis was driven by 38 nonresponsive lines that mounted a qualitatively distinct response to infection. These observations 39 support an important role for host genetic diversity in determining BCG efficacy, and provide a new 40 resource to rationally develop more broadly efficacious vaccines. 41 42 Importance: Tuberculosis (TB) remains an urgent global health crisis, and the efficacy of the 43 currently used TB vaccine, M. bovis BCG, is highly variable. The design of more broadly-efficacious 44 vaccines depends on understanding the factors that limit the protection imparted by BCG. While these 45 complex factors are difficult to disentangle in natural populations, we used a model population of mice 46 to understand the role of host genetic composition to BCG efficacy. We found that the ability of BCG 47 to protect an individual genotype was remarkably variable. BCG efficacy did not depend on the 48 intrinsic susceptibility of the animal, but instead correlated with qualitative differences in the immune 49 response to the pathogen. These studies suggest that host genetic polymorphism is a critical 50 was developed in the 1920's. In the subsequent decades, studies in different geographic regions and 76 ethnic populations have produced widely variable estimates of BCG's effect. In several populations, 77 BCG efficacy is estimated to be greater than 75%. However, in regions where TB remains endemic, 78 no significant protection from pulmonary TB in adults can be detected (19, 20) . This variable efficacy 79 could be due to differences in the vaccine strain or preparation, the environment, or the genetic 80 background of the host. The roles of genetic variation in the vaccine strain (21-24) and previous 81 exposure to environmental mycobacteria (25-27) have been investigated extensively. In contrast, the 82 role of host genetic variation in BCG efficacy has been more difficult to quantify. It is clear that 83 variations in many immune mediators are highly heritable (28-30). Many of these heritable variations 84 affect mediators that are likely to be relevant to Mtb immunity, such as the number of central memory 85
T cells or abundance of cytokines such as IL-12p40, GM-CSF, IFNa, and IL-6 (31). Indeed, 86 numerous studies suggest that the immunological response to mycobacterial infection (32-35) and 87 BCG vaccination (36, 37) is heritable. However, the relationship between these immunological 88 markers and vaccine efficacy is unknown and very difficult to address in natural populations. Thus, 89 while there is reason to suspect that BCG efficacy is influenced by genetic variation, it has proven 90 difficult to dissociate these effects from other confounding variables. In particular, the effect of BCG 91 is difficult to dissociate from the intrinsic TB susceptibility of each individual in a natural population. 92
93
In theory, animal models could be used to dissect the role of genetic diversity in vaccine protection. 94
However, while the mouse model of TB has been very useful for understanding the mechanisms 95
underlying Mendelian susceptibility to TB, this approach has proven less useful for understanding the 96 complex trait genetics that that have been shown to underlie TB susceptibility in mice, with only 2 host 97 loci so-far identified from forward-genetic approaches (38-40). A fundamental limitation of the classic 98 inbred strains of M. musculus domesticus that are generally used to model TB is their genetic 99 homogeneity, as 90-95% of these animals' genomes are estimated to be functionally identical (41). As 100 a result, these mouse strains mount qualitatively comparable immune responses to this infection and 101 vary only modestly in their susceptibility to Mtb (42). In virtually every strain, Mtb grows 102 logarithmically for 2-3 weeks, at which point bacterial growth is restricted by a strong Th1-biased 103 CD4+ T cell response. Immunity depends largely on CD4+ T cell-derived IFNg, and allows the 104 animal to survive for several months harboring a relatively constant burden of bacteria. BCG 105 vaccination also produces a relatively homogenous effect in a variety of standard lab strains of mice 106 (43-45), accelerating the initiation of adaptive immunity by several days, reducing the peak burden of 107 bacteria by approximately 10-fold (46) and extending survival (47). It is often noted that the mouse 108 model does not reproduce many aspects of TB disease seen in humans or non-human primates, 109
including variable histopathology (48), progressive bacterial killing (49), and widely varying 110 susceptibility ((e.g. 50). While these discrepancies are generally attributed to species difference, the 111 lack of variation observed in mice could also reflect the low genetic diversity between classical inbred 112 strains (51). Thus, the true range of TB-related traits that can be modeled in mice remains unclear. 113
114
Tractable model systems that incorporate relevant genetic diversity could be used to decipher the 115 genetic determinants of both TB susceptibility and vaccine protection. Recently, a number of related 116 model outbred mouse populations have been developed based on the same set of eight genetically 117 diverse founder lines, which represent all three M. musculus subspecies. Outbred progeny of these 118 strains, called the Diversity Outbred (DO) population represent similar genetic diversity as a human 119 outbred population (52, 53) and display a remarkable heterogeneity in Mtb susceptibility (54). 120 However, the completely outbred structure of this population imposes several limitations on the 121 resource. Most notably, each genotype is represented by only a single animal. As a result, it is 122 difficult to quantify the genotype-specific effect of an intervention, such as vaccination. To 123 complement this resource, panel of recombinant inbred lines derived from the same founders was 124 generated and called the "Collaborative Cross" (CC) (55, 56) . The CC panel retains the genetic 125 diversity of DO animals, but allows each genotype to be infinitely reproduced. We took advantage of 126 the unique structure of the CC population to investigate the relationship between host genotype, TB 127 susceptibility, and BCG efficacy. We found that the panel of parental and recombinant CC strains 128 (hereafter named "diversity panel") reproduced many aspects of outbred populations, and encompassed 129 reproducible phenotypes that extend well beyond those observed in standard inbred strains. Using the 130 diversity panel, we found that BCG efficacy is genetically dissociable from TB susceptibility and 131 correlates with intrinsic immune biases in the strains. This new genetic resource identified an 132 important role for host genetic diversity in vaccine efficacy and provides new approaches to 133 understand the immunological basis of protection and to optimize vaccines for outbred populations. To characterize the range of Mtb susceptibility represented in the diversity panel, we infected groups 149 of each genotype with H37Rv via the aerosol route and monitored disease over time. When the 150 population was analyzed in the aggregate ( Fig 1A, B and C), we observed a range of susceptibility 151 similar to that observed in completely outbred 'DO' animals derived from the same founders (54). 152
Lung and spleen CFU burden varied over by range of 1000-10,000 fold, and some animals required 153 euthanasia after only 4 weeks of infection. When the panel was assessed at the genotype level ( Fig 1D,  154 E and F), we found that these differences in susceptibility were reproducible within each genotype and 155 were therefore highly heritable. Based on bacterial burden in the lung at 6 weeks post-infection, the 156 genotypes could be ranked based on susceptibility ( Fig 1D) . The B6 strain, generally considered to be 157 was the first indication that this strain progressively kills Mtb over time (as shown in the subsequent 164 studies presented below, see Fig. S2 ). In contrast, the both WSB and CC042 strains were unable to 165 control bacterial replication (p=0.0001 for WSB, p<0.0001 for CC042 compared to B6 via one-way-166 ANOVA with Tukey's multiple comparison test), lost weight, (p=0.0039 for WSB, p=0.0004 for 167 CC042 compared to B6 via one-way-ANOVA with Tukey's multiple comparison test), and were 168 moribund after only 4 weeks of infection. Thus, these genotypes were as susceptible as knockout mice 169 lacking critical aspects of CD4+ T cell-driven immunity, such as NOS2 (60) or MHCII (61). 170
171
The ability to accurately measure multiple metrics of disease over time in reproducible lines, allowed 172 the identification of traits that are genetically separable. For example, the rate at which bacteria 173 disseminate from the lung to spleen was variable across the panel. Despite harboring similar numbers 174 of Mtb in the lung at 3 weeks post-infection, NOD, and the wild-derived strain of M. musculus 175 musculus, PWK, harbored significantly fewer CFU in their spleen than B6 (p = 0.020 for NOD vs B6 176 and p = 0.028 for PWK vs B6, by one-way ANOVA with Tukey's multiple comparison test). In the 177 spleens of PWK mice, Mtb burden increased between 3 and 6 weeks post-infection, indicating Mtb is 178 able to replicate at this site. Thus, the early deficit in spleen CFU in this genotype could reflect 179 delayed dissemination from the lung, which occurs during this period and has been previously shown 180 to vary with host genotype (62). We conclude that the diversity panel encompasses a wide variation in 181 TB susceptibility traits, and different aspects of disease may be controlled by distinct genetic 182 polymorphisms. 183
184

TB pathogenesis and immune response differ qualitatively between strains. 185
The polygenic basis of susceptibility in the diversity panel suggested that distinct inflammatory and/or 186 remarkably low levels of this cytokine that were at or below the limit of detection (LOD) of the assay 208 (LOD = 17 pg/mL). Splenocytes from PWK and CAST both produced IFNg upon polyclonal 209 stimulation ex vivo ( Fig S1) , indicating that these cells were capable of producing cytokine that was 210 detectable in our assay. Thus, the lack of IFNg expression in the lung of PWK, CAST, and CC042 211 mice was not due to an inherent inability to express the cytokine. Instead, these lines appear to mount 212 a distinct response to Mtb infection, and the relative resistance of the CAST and PWK lines indicates 213 that these responses can be effective in the absence of high levels of IFNg. 214 215
Host genotype determines BCG efficacy 216
To determine if genetic polymorphism could influence the degree of protection conferred by 217 vaccination, we immunized a panel of diverse mouse strains with BCG by the subcutaneous route. The 218 mice used for the vaccination study consisted of the same CC founder strains, the highly-resistant 219 We initially analyzed this large panel as an aggregate population with 53-66 animals per group. As 226 seen previously, the bacterial burden in lung and spleen of these animals varied widely, and 227 vaccination did not alter this variation ( Fig 3A-B) . BCG vaccination reduced the mean Mtb burden in 228 the lung or spleen by 1.7 to 4 fold at each time point, but even with this large group size the BCG-229 mediated reduction of bacterial burden was only statistically significant at 4 weeks post-infection. 230
Thus, no durable protection from Mtb growth could be detected in the aggregated data, which mirrors 231 the lack of protection conferred by BCG in many natural outbred populations. 232
233
When the data were analyzed at the genotype level, it became clear that the variation in CFU burden 234 was driven by genotype-specific effects on both Mtb susceptibility and vaccine efficacy ( Fig. 3C-D) . 235
Using the reduction in Mtb burden as a metric of vaccine efficacy, we defined "protection" as a 236 decrease in CFU of greater than 0.5 log 10 that reached statistical significance. Based on these criteria, 237 only a subset of genotypes was protected by vaccination. Consistent with previous literature, BCG 238 reduced the bacterial load in lungs and spleen of B6 mice by approximately ten-fold. This response 239 was shared in three other lines, two recombinants (CC001 and CC002) and the wild-derived WSB line. 240
In these genotypes, BCG exposure reduced Mtb load by 10-100 fold. Notably, these were the only 241 genotypes in which vaccination protected the lung. BCG conferred protection in spleen but not lung of 242 four additional lines (129, CC019, CAST and A/J). The remaining genotypes were not protected by 243 vaccination in either organ at any time point. In these non-responding lines, BCG vaccination either 244 had no effect on Mtb burden or was associated with an increase in mean CFU, which reached statistical 245 significance for the NZO genotype (P<0.05, by t-test). In most cases, increased bacterial burden 246 correlated with weight loss (Fig. 3D ). In WSB, CC002, and B6 genotypes, BCG vaccination reduced 247 bacterial burden and significantly reversed weight loss at one of the two time points. The effect of 248 BCG on CFU and weight loss were discordant for the NZO and CC001 genotypes, reflecting unique 249 phenotypes that will be discussed below. 250 TB susceptibility and BCG efficacy are genetically separable traits. The ability to serially evaluate 252 the same host genotype allowed multiple traits to be independently measured in the vaccinated and 253 unvaccinated state. To investigate potential mechanisms that determine vaccine efficacy, we searched 254 for correlates of BCG-mediated protection among the traits measured during primary infection. These 255 traits included lung cytokine measurements as a metric of adaptive immunity, CFU as a measure of 256 antimicrobial capacity, and weight loss as a surrogate for systemic disease. Figure 4A, green box) . The cluster did not contain any traits related to 262
Mtb susceptibility in the unvaccinated state, and no specific correlation between Mtb susceptibility and 263 BCG efficacy was evident ( Fig 4B-C) . Furthermore, BCG caused the largest reduction in CFU in 264 CC001 and WSB, the most resistant and susceptible lines in the study, respectively (Fig. 4B, orange  265 and purple). Thus, Mtb susceptibility and BCG efficacy were genetically separable. 266
267
In addition to all traits related to BCG protection, the BCG efficacy-related cluster of traits also 268 included another metric of immune response that correlated strongly with the degree of BCG-mediated 269 protection, the early production of IFNg by unvaccinated animals (Fig. 3D-E only marginally extended the survival of the highly-susceptible WSB strain from 4 to 6 weeks, and 280 ultimately did not protect this strain from disease. Conversely, even without vaccination, the resistant 281 CC001 and CC002 strains had the remarkable ability to kill 90-95% of Mtb between 4 and 14 weeks 282 postinfection (Fig 3 and Fig S2) . As a result, unvaccinated animals of these genotypes harbored a 283 similar bacterial burden at the later time point as the vaccinated B6 group. The relative resistance of 284 this CC001 likely explains its ability to gain weight throughout the infection, regardless of BCG 285 vaccination ( Fig 3D) . 286
287
We also found that mice could benefit from vaccination even if Mtb burden was not reduced. For 288 example, even though BCG-vaccinated NZO mice harbored significantly more Mtb in their lungs than 289 their unvaccinated counterparts at 4 weeks post-infection, vaccination still reversed Mtb-induced 290 weight loss between 4 and 14 weeks ( Fig 3D) . The NZO mouse strain has been described to develop a 291 polygenic form of type II diabetes at a similar age as the animals in our study (65). As chronic 292 hyperglycemia can increase Mtb susceptibility in mice (66, 67), we hypothesized that an interaction 293 between vaccination and diabetes initiation might underlie the paradoxical effect of BCG on Mtb 294 burden and weight loss. Indeed, while 5 of 6 unvaccinated animals were found to have fasting blood 295 glucose levels above 500 mg/dL at 14 weeks post-infection, 0 of 6 vaccinated animals were diabetic 296 ( Fig 5A-B) . In the NZO genotype, diabetes strongly predicted weight loss but not CFU (Fig 5C-D) . 297
Our diversity mouse panel also included NOD mice that develop autoimmune type I diabetes (68). No 298 significant effect of BCG on either Mtb burden or blood glucose concentration was evident in this 299 strain, possibly due to the variable penetrance of diabetes ( Fig S2J) . Thus, the major protective effect 300 of BCG in Mtb-infected NZO mice appears to be the prevention of type II diabetes. Taken together, 301 our observations in the genetic diversity panel suggests that while the protective efficacy of BCG can 302 be separated from TB susceptibility, the ultimate effect of vaccination on the outcome of infection is 303 influenced by a variety of factors including intrinsic susceptibility to TB and complex interactions with 304 co-morbidities such as diabetes. 305 306
Discussion 307
Predicting TB risk and rationally designing more effective interventions will ultimately require 308 understanding the mechanisms that control the outcome of Mtb infection in a genetically diverse 309
population. An ideal experimental model to dissect these mechanisms would encompass relevant 310 genetic diversity and allow the serial evaluation of genetically identical individuals. To create such a 311 population, we took advantage of the Collaborative Cross project, which identified genetically-diverse 312 founder lines and generated recombinant inbred animals in which this diversity was reassorted to 313 produce more extreme phenotypes. Our studies using this panel extend the phenotypic diversity 314 described in the species and allowed the contribution of host genetics to TB susceptibility and BCG 315 efficacy to be independently assessed. 316
317
The course of Mtb infection in the standard "mouse model" (B6 inbred strain) is often contrasted with 318 the diversity of TB-related disease that is apparent in other species. For example, while Mtb can 319 replicate continually at some sites in the lungs of cynomolgus macaques, Mtb is efficiently killed in 320 most of the granulomas (49). These studies are consistent with observations from human autopsies, 321 which similarly suggest that Mtb is eradicated from many granuloma and only replicates in a minority 322 of sites (69). In contrast, with the exception of a few susceptible substrains (54, 70), Mtb infection of 323 standard lab strains of M. musculus domesticus follows a very similar course; Mtb replication can 324 generally be controlled, but the mice are unable to clear the pathogen or even to significantly reduce 325 the lung bacterial burden during the persistent phase of infection when the Mtb burden remains stable. 326
Our studies suggest that this homogeneity in TB pathogenesis reflects the genetic homogeneity of these 327 strains, but not the phenotypic diversity of the species. Of course, the mouse lines used in this study 328 may not capture all diversity previously described in mouse substrains. Mtb. This line has also been recently reported to be modestly susceptible to influenza A virus 340 infection (71). However, these animals are otherwise healthy and able to control the replication and 341 dissemination of BCG, suggesting a fairly specific defect in immunity to Mtb. While the CAST line of 342 M. musculus castaneous, and PWK line of M. musculus musculus appeared similarly susceptible to TB 343 as many standard lines, their response to infection differed from other genotypes in several respects. 344
The lungs of CAST mice displayed a paucity of inflammatory infiltrate, relative to other mice that 345 harbored similar bacterial burdens, a trait also reported for this genotype during influenza virus 346 infection (71). PWK animals were able to delay the dissemination of Mtb from the lung to the spleen. 347
Most strikingly, both CAST and PWK produced barely detectable levels of IFNg during infection. 348
While this cytokine is critical for Mtb immunity in B6 mice, these strains were still able to control 349 bacterial replication. CD4+ T cells have been shown to control Mtb growth through IFNg-independent 350 mechanisms in several settings (72, 73), and Th17 cells have been specifically implicated in protection 351 (74). Together, these observations suggest that these highly divergent mouse lines might preferentially 352 depend on non-Th1 biased CD4+ T cell responses for Mtb immunity. 353
354
The structure of our mouse population allowed us to determine that BCG efficacy is controlled 355 independently of TB susceptibility in naïve animals. These observations suggest that even the most 356 susceptible individuals can benefit from vaccination. However, the genetic basis of vaccine-conferred 357 protection remains unclear. The animals in our panel encode diverse MHC haplotypes, raising the 358 possibility that H2 polymorphism could influence the degree of protection (40). However, MHC 359 haplotype alone is unlikely to explain the dramatic differences that we observed, since BCG produces a 360 large and diverse array of potential antigens. In addition, two strains in our panel (129 and B6) shared 361 the same H2 haplotype and were differentially protected, further indicating that additional mechanisms 362 determine BCG efficacy. Similarly, while the relative ability to eradicate BCG could control efficacy, 363 previous studies found that this vaccine protects animals of widely varying BCG susceptibilities, which 364 were determined by Nramp1 (Slc11a1) polymorphism (44). Instead, the observed correlation between 365 the propensity of an unvaccinated strain to produce IFNg after Mtb infection and the degree of BCG-366 induced protection suggests that intrinsic bias in the anti-mycobacterial immune response could 367 influence vaccine efficacy. While this correlation was driven by both classical and wild-derived lines, 368 the CAST and PWK were particularly strong outliers. These strains made very low levels of IFNg 369 after infection and received virtually no benefit from BCG. Thus, it is possible that while BCG is a 370 robust inducer of canonical anti-mycobacterial Th1 responses, it is unable to stimulate the immune 371 response(s) that protect these highly-divergent strains. 372
373
The low and variable degree of protection elicited by BCG in natural populations could be due to 374 either a general lack of efficacy or a differential effect in distinct individuals. It is important to 375 understand the relative importance of these two factors, since entirely different approaches are 376 necessary to overcome them. Our observations using a model population of genetically diverse mice 377 indicate that genetic diversity in the host population could be a major factor limiting BCG efficacy. 378
Based on these findings, it is not clear that optimizing a vaccine to protect a single standard lab strain 379 of mouse will produce an intervention that is broadly efficacious in an outbred population, or even that 380 a single vaccine is capable of protecting genetically diverse individuals. Instead, optimizing a vaccine 381 or set of vaccines to protect non-responding strains may represent a more effective strategy. Each data point in panels B-E is the average of 3 to 6 mice per genotype. Note that NOD mice were 445 not displayed on the correlation plots due to the highly variable response of this strain (see Figure S2J ). 
